The DPP-4 Inhibitor Vildagliptin Is Linked to Fewer Microvascular Complications Than Sulfonylureas
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Only registered members have full access to PracticeUpdate content.